MELBOURNE, Australia and INDIANAPOLIS, Indiana — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2. IPAX-Linz is a single-arm Phase 2...
Latest News
MELBOURNE, Australia and INDIANAPOLIS, Ind. — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in...
MELBOURNE, Australia and INDIANAPOLIS, Indiana — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate1, has been validated and accepted for review. The application, covering commercially significant European markets2, has now...
ANDOVER, Mass. — TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with...
ANDOVER, Mass. — TellBio, Inc., a medical technology company focused on revolutionizing the management of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data demonstrating that analysis of circulating tumor cells using TellDx can predict patient response to the...
Toronto, Canada — Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) , a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced that it will deliver an industry presentation at the 2025 Myeloma Canada MRD Testing Implementation Summit, taking place November 14–15. Dr. Yulia Shifrin, Laboratory...
MIAMI, FLORIDA – Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced new laboratory findings demonstrating that Telomir-1 kills aggressive pancreatic cancer cells. Study Summary In laboratory studies using human pancreatic cancer (PANC-1) cells, Telomir-1 produced a...
MIAMI, Florida – Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir”), a leader in age-reversal science, today announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human prostate cancer cells. It was found that Telomir-1 actively suppresses cancer growth rather than...
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival – highlighting Telomir-1’s potential to reverse key hallmarks of aging MIAMI, FL – Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the “Company,” an emerging leader in age-reversal science, today announced...
MIAMI, FLORIDA – Telomir Pharmaceuticals (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC). The study was conducted in...